InterCure Ltd.
INCR Healthcare Drug Manufacturers Specialty & Generic
InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.
Follow INCR
Alert me
InterCure Ltd. (INCR) P/E ratio
As of 5 November 2026, InterCure Ltd. (INCR) trades at a P/E ratio of 6.2×. Over the past ten years it has ranged from 1.1× (March 2023) to 290× (April 2021); the current reading is higher than 74% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 20.5× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 1.7× | (42.77%) |
| FY2024 | 3.0× | 22.31% |
| FY2023 | 2.5× | 10.65% |
| FY2022 | 2.2× | (94.61%) |
| FY2021 | 41.2× | (19.10%) |
| FY2020 | 50.9× | 0.00% |
| FY2019 | 50.9× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 16.1× | 686.91% |
| Mar 2023 | 2.0× | (8.05%) |
| Dec 2022 | 2.2× | (34.55%) |
| Sep 2022 | 3.4× | (39.84%) |
| 9 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RMTI Rockwell Medical, Inc. compare | n/m |
| CPIX Cumberland Pharmaceuticals Inc. compare | n/m |
| SCYX SCYNEXIS, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| TLPH Talphera, Inc. compare | n/m |
| CPHI China Pharma Holdings, Inc. compare | n/m |
| INCR InterCure Ltd. | 6.2× |
| ZYBT Zhengye Biotechnology Holding Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)